LPA抗体 新品

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Immunofluorescence analysis of HepG2 cells using LPA mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human liver cancer tissues using LPA mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human breast cancer tissues using LPA mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human rectum cancer tissues using LPA mouse mAb with DAB staining.    

  
  

Lipoprotein(a) [Lp(a)] antibodies are immunological tools designed to target and study Lp(a), a unique lipoprotein particle associated with cardiovascular disease risk. Lp(a) consists of a low-density lipoprotein (LDL)-like core linked to apolipoprotein(a) [apo(a)], a glycoprotein homologous to plasminogen. Elevated Lp(a) levels are recognized as an independent risk factor for atherosclerosis, thrombosis, and aortic valve stenosis due to its pro-atherogenic and pro-thrombotic properties.

Lp(a)-specific antibodies play a critical role in research and diagnostics. They enable quantitative measurement of Lp(a) in clinical assays, distinguishing it from LDL by targeting apo(a)'s distinctive kringle IV type 2 repeats. Therapeutic antibodies targeting Lp(a) are also under investigation to mitigate cardiovascular risk. For example, monoclonal antibodies and antisense oligonucleotides aim to reduce Lp(a) synthesis or enhance its clearance. Pelacarsen, an antisense therapy in clinical trials, uses antibody-guided mechanisms to lower Lp(a) levels.

Research on Lp(a) antibodies continues to advance understanding of its pathophysiological roles and therapeutic potential. Their development addresses the unmet need for targeted therapies in individuals with genetically elevated Lp(a), offering promise for personalized cardiovascular risk management.